Precisely Empowers Customers to Unlock Business Value from ESG Reporting with Trusted Data
25.4.2023 16:00:00 EEST | Business Wire | Press release
Precisely, the global leader in data integrity, today announced that it is partnering with customers worldwide to build trust in data for effective ESG reporting processes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230425005089/en/
(Photo: Business Wire)
The powerful combination of the Precisely Data Integrity Suite and expert strategic services allows customers to easily combine multiple sources of ESG data for real-time insights, improve confidence in the data quality of ESG metrics, ensure data governance while maintaining compliance with industry regulations, and enrich data with additional datasets to help reveal hidden context. Organizations leveraging data integrity in ESG reporting processes see tangible results such as:
- Improved combination and alignment of fundamental ESG data with datasets that add context and meaning, such as geographic, demographic, or economic data
- Enhanced capture and organization of ESG data from multiple sources, breaking down siloes and making it available in real-time
- More robust standards and controls that ensure ESG data is accurate, consistent, and fit for purpose across operational and analytical systems
- Better governance of data storage, access, use, and exchange between systems while maintaining privacy, security, and compliance with complex regulations
Organizations are increasingly recognizing a need to overhaul ESG reporting, with 41% of finance leaders recently admitting that their current processes would not stand up to the scrutiny of basic assurance standards. With new research from IDC showing that data management concerns are the leading driver for ESG investment, there is no better time for businesses to leverage trusted data to drive accurate reporting processes, achieve meaningful outcomes, and unlock true business value from ESG-focused initiatives.
Vontobel, a globally active investment firm with Swiss roots, have ensured they are ahead of the curve by partnering with Precisely to focus on data integrity. The firm not only ensures that all investment strategies are ESG compliant, but goes one step further by setting its own additional sustainable investment criteria to ensure the best possible investment solutions for clients. The optimization of the ESG data processes for the portfolio valuation is crucial - this includes comprehensive data analysis as well as quality and completeness checks.
"Collecting data is nothing new for investment companies, but the challenge now is how to cater to the new volumes of data needed for meaningful ESG measurement and figure out which data elements are the most important,” said Christina Schack, Head of Data Platform at Vontobel. “Using proper tools to automate data quality checks in the data cleansing process is very important to handle and control the immense amount of ESG data. Implementing automated checks and ingestion of the data has greatly helped to reduce the manual work and achieve more accurate analysis for investment strategies."
Verisk Maplecroft, a leading global risk consultancy firm and specialist in sustainability, resilience, and ESG, also recognizes the importance of ESG reporting powered by accurate, consistent, and contextual data, particularly when combined with the right expertise:
“A more powerful way to approach ESG reporting is to hold it to the same standard of governance, processes, controls, assurance, and expertise that you would with your financial reporting,” said Mikkel Skougaard, Director of ESG Reporting and Strategy at Verisk Maplecroft. “Developing a data-driven ESG report is the most important factor, but this needs to be supported with high-quality contextual narrative in order to unlock maximum value.”
Skougaard will be in attendance at Precisely’s upcoming Data Integrity Summit, Trust ’23, joining Precisely CRO Pat McCarthy and Matthew Rusk, Head of Global Reporting Initiative (GRI) North America for a panel discussion on the importance of trusted data in harnessing true business value from ESG reporting, as well as advice for navigating evolving regulations and consumer expectations. The session takes place on May 17 with registration now open.
“Modern business practices demand complete transparency,” said McCarthy. “Investors, employees, and consumers alike want to know the companies they’re investing in, working for, and buying from not only meet their personal standards of ethics but are doing their part to create a better world. To stay compliant and achieve meaningful outcomes businesses need to prioritize data integrity in sustainability reporting and build trust in the data fueling their decisions.”
Learn more about the exciting speaker line up at Trust ’23 and register for your free place today.
About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005089/en/
Contact information
Press Contact
Emma Forrest (Global)
press@precisely.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
